Brief: Ascentage Says NMPA Accepts New Drug Application For Novel Bcl-2 Inhibitor Lisaftoclax
17/11/2024 10:42
Nov 17 (Reuters) - Ascentage Pharma Group International
6855.HK :
* SAYS CHINA'S NMPA ACCEPTS NEW DRUG APPLICATION FOR CO'S
NOVEL
BCL-2 INHIBITOR LISAFTOCLAX
Source text
Further company coverage: 6855.HK
(Reporting by Hong Kong newsroom)
((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up